Anti-inflammatory and pain release drug
Fargesic
Fargesic

 Dosage Forms:

  • Fargesic capsule contains Acetaminophen: 325 mg, Caffeine: 40 mg and Ibuprofen: 200 mg.

Drug Group

Analgesic, CNS stimulant, Non-Steroidal Anti-Inflammatory Drug (NSAID)

Mechanism

Fargesic capsule contains acetaminophen, a non-opiate, non-salicylate analgesic and antipyretic, caffeine a methylxanthine CNS stimulant and Ibuprofen a non-steroidal anti-inflammatory drug.

Indications

Fargesic capsules are used for the treatment of mild to moderate pain and fever.

Dosage and Administration:

  • Because capsules contains 3 active ingredients dosage should be adjusted according to this three active. In treatment of mild to moderate pains one capsule every 8 hours should be used.

Precautions and Warnings

Patients with a history of hypersensitivity to any of Cetirizine constituents.

Side Effects

Side-effects of acetaminophen are rare and usually mild, although haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Skin rashes and other hypersensitivity reactions occur occasionally. Side-effects of ibuprofen are edema, dizziness, headache, nervousness, Itching, rash, fluid retention, dyspepsia, vomiting, abdominal pain/cramps/distress, heartburn, nausea, diarrhea, constipation, flatulence, epigastric pain, appetite decreased, tinnitus. Side-effects of caffeine are angina, arrhythmia (ventricular), chest pain, flushing, palpitation, sinus, tachycardia, tachycardia (supraventricular), vasodilatation, agitation, delirium, dizziness, hallucinations, headache, insomnia, irritability, psychosis, restlessness, urticaria, esophageal sphincter tone decreased, fasciculations, intraocular pressure increased (>180 mg caffeine), miosis, dieresis.
Interactions: The risk of acetaminophen toxicity may be increased in patients receiving other potentially hepatotoxic drugs or drugs that induce liver microsomal enzymes. The absorption of acetaminophen may be accelerated by drugs such as metoclopramide. Excretion may be affected and plasma concentrations altered when given with probenecid. Colestyramine reduces the absorption of acetaminophen if given within 1 hour of Acetaminophen. Like theophylline caffeine undergoes extensive metabolism by hepatic microsomal cytochrome P450 isoenzyme CYP1A2, and is subject to numerous interactions with other drugs and substances which enhance or reduce its metabolic clearance. Interactions involving NSAIDs include enhancement of the effects of oral anticoagulants (especially by azapropazone and phenylbutazone) and increased plasma concentrations of lithium, methotrexate, and cardiac glycosides.

Pregnancy and Lactation

Pregnancy category C/D. Enters breast milk/compatible.

Packaging

  • 10 capsules in one blister. 2 blisters in a box.
Meloxicam
Meloxicam

 Dosage Forms: 

  • 7.5 mg and 15 mg tablets.

Drug Group

Analgesic and Anti-inflammatory agent

Mechanism

Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs.

Indications

Carefully consider the potential benefits and risks of meloxicam and other treatment options before deciding to use it. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goal. Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.

Dosage and Administration

For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of meloxicam is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of meloxicam is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. The maximum recommended daily oral dose of meloxicam is 15 mg regardless of formulation.

Precautions and Warnings

Caution should be used when initiating treatment with meloxicam in patients with history of GI disease, asthma, hypertension, CVD or risk factors, fluid retention or heart failure. Monitor patients with advanced renal disease may impair ability to drive or operate machinery. Anemia is sometimes seen in patients receiving NSAIDs, including meloxicam. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur, meloxicam should be discontinued.

Side Effects

Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting, constipation, accident household, edema, fall, pain, influenza-like symptoms, dizziness, headache, pharyngitis, upper respiratory tract infection, coughing, pruritus, rash, Joint related signs and symptoms, musculoskeletal and connective tissue signs and symptoms, anemia, arthralgia, back pain, insomnia, micturition frequency, urinary tract infection
Interactions: Meloxicam may reduce effects of antihypertensivites. Increased clearance with bile acid sequestrants e.g. colestyramine. Increased risk of renal failure with diuretics; may reduce natriuretic effects of furosemide and thiazides. May increase toxicity of methotrexate. Potentially fatal: May increase plasma concentrations and toxicity of lithium. Increased risk of severe GI effects with aspirin, warfarin.

Pregnancy and Lactation

Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. Meloxicam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk; because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from meloxicam, a decision should be made whether to discontinue.

Packaging:

  • 10 tablets in one blister. 3 blisters in a box.
Diclofenac sodium
Diclofenac Sodium

Dosage Forms:

  • 100 mg extended-release capsules

Drug Group

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism

Diclofenac sodium extended-release capsules exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of diclofenac sodium, like that of other NSAIDs, is not completely understood but may be related to cyclooxygenase inhibition.

Indications

For relief of the signs and symptoms of osteoarthritis, for relief of the signs and symptoms of rheumatoid arthritis.

Dosage and Administration:

  • For the relief of osteoarthritis, the recommended dosage is 100 mg once daily. For the relief of rheumatoid arthritis, the recommended dosage is 100 mg once daily. In the rare patient where Diclofenac Sodium-ER 100 mg/day is unsatisfactory, the dose may be increased to 100 mg twice daily. If the benefits outweigh the clinical risks of increased side effects. After observing the response to initial therapy with Diclofenac Sodium-ER, the dose and frequency should be adjusted to suit an individual patient’s needs.

Precautions and Warnings

Diclofenac is contra-indicated in patients with severe hepatic or renal impairment. in patients with a history of hypersensitivity to aspirin or any other NSAIDs which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAIDs), and in coagulation defects.

Side Effects

Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting. Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes and tinnitus, photosensitivity, sweating increased and myalgia.
Interactions: Aspirin: potential of increased adverse effects Methotrexate: enhance the toxicity of methotrexate Cyclosporine: increase cyclosporine’s nephrotoxicity ACE Inhibitors: diminish the antihypertensive effect of ACE inhibitors. Furosemide, Thiazide and Thiazide-like Diuretics: Diclofenac -XR can reduce the natriuretic effect of furosemide and thiazides. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.

Pregnancy and Lactation

Pregnancy category C. Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be used with caution during breast-feeding.

 Packaging:

  • 10 capsules in one blister. 3 blisters in a box.